Abstract
Trastuzumab is a recombinant humanized monoclonal antibody directed against HER2. Several issues about its optimal use,mechanism of action or resistance still await convincing answers. Results of large-scale randomized trials and preclinical study might answer these questions. This review summarizes current knowledge about trastuzumab treatment.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Aromatase Inhibitors / administration & dosage
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Clinical Trials as Topic
-
Disease-Free Survival
-
Drug Resistance, Neoplasm
-
Female
-
Heart Failure / chemically induced
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / mortality
-
Receptor, ErbB-2 / analysis*
-
Stomach Neoplasms / chemistry
-
Stomach Neoplasms / drug therapy
-
Survival Rate
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Aromatase Inhibitors
-
Receptor, ErbB-2
-
Trastuzumab